Cart
sales@molnova.com
P7C3-OMe
CAS No. 313268-18-7
P7C3-OMe ( —— )
Catalog No. M22944 CAS No. 313268-18-7
P7C3-OMe, a pro-neurogenic agent, has therapeutic benefits in neurodegenerative diseases. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 88 | In Stock |
|
| 5MG | 140 | In Stock |
|
| 10MG | 205 | In Stock |
|
| 25MG | 417 | In Stock |
|
| 50MG | 614 | In Stock |
|
| 100MG | 872 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameP7C3-OMe
-
NoteResearch use only, not for human use.
-
Brief DescriptionP7C3-OMe, a pro-neurogenic agent, has therapeutic benefits in neurodegenerative diseases. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer.
-
DescriptionP7C3-OMe, a pro-neurogenic agent, has therapeutic benefits in neurodegenerative diseases. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number313268-18-7
-
Formula Weight504.21
-
Molecular FormulaC22H20Br2N2O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (198.33 mM)
-
SMILESOC(CNC1=CC=CC(OC)=C1)CN2C3=C(C4=C2C=CC(Br)=C4)C=C(Br)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pieper AA, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010 Jul 9;142(1):39-51.
molnova catalog
related products
-
SPR741 TFA
SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule.
-
Diisohexyl phthalate
Diisohexyl phthalate is a class of dialkyl phthalate esters and a plasticizer.
-
Etifoxine hydrochlor...
Etifoxine is an anxiolytic and anticonvulsant drug.?Unlike benzodiazepines, etifoxine appears to produce its anxiolytic effects by binding to β2 and β3 subunits of the GABAA receptor complex, and so is acting at a different target site to benzodiazepines, although the physiological effect that is produced is similar to that of benzodiazepines.
